Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft

Advanced cutaneous squamous cell carcinoma (cSCC) is treated with chemotherapy and/or radiotherapy, but these typically fail to achieve satisfactory clinical outcomes. There have been no preclinical studies to evaluate the effectiveness of eribulin against cSCC. Here, we examine the effects of eribu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Che-Yuan, Yanagi, Teruki, Maeda, Takuya, Nishihara, Hiroshi, Miyamoto, Kodai, Kitamura, Shinya, Tokuchi, Keiko, Ujiie, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224945/
https://www.ncbi.nlm.nih.gov/pubmed/37244956
http://dx.doi.org/10.1038/s41598-023-35811-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224945/
https://www.ncbi.nlm.nih.gov/pubmed/37244956
http://dx.doi.org/10.1038/s41598-023-35811-3

Ejemplares similares